Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II
- To determine the percentage of primary acute myeloid leukemia (AML) samples with
increased Stat3 signaling pathway activity.
- To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3
activation to low- and high-doses of cytokines.
- To evaluate the expression levels of Stat3 protein and the upstream and downstream
regulators of Stat3 activation.
- To classify samples according to a Stat3 activation pattern and correlate this result
with event-free survival (EFS) and overall survival (OS).
OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to
cytokine levels, and expression level of proteins known to influence stat activity by flow
cytometry and western blot assays. Results are also compared with prognostic variables
determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.
Correlation of constitutive pStat3 with inducible pStat3
Michele S. Redell, MD, PhD
Texas Children's Cancer Center
United States: Federal Government